CC
ALXN

Curian Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Curian Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,587
Closed -$2.97M – 412
2015
Q4 		$2.97M Sell
15,587
-32,595
-68% -$5.69M 0.22% 102
2015
Q3 		$7.54M Sell
48,182
-16,655
-26% -$3.04M 0.2% 125
2015
Q2 		$11.7M Buy
64,837
+10,987
+20% +$1.9M 0.2% 129
2015
Q1 		$9.33M Buy
53,850
+13,160
+32% +$2.38M 0.16% 172
2014
Q4 		$7.53M Sell
40,690
-5,647
-12% -$1.05M 0.13% 195
2014
Q3 		$7.68M Sell
46,337
-317
-0.7% -$52.1K 0.14% 190
2014
Q2 		$7.29M Buy
46,654
+11,486
+33% +$1.81M 0.13% 194
2014
Q1 		$5.35M Sell
35,168
-21,504
-38% -$3.42M 0.1% 223
2013
Q4 		$7.53M Sell
56,672
-1,437
-2% -$172K 0.13% 174
2013
Q3 		$6.75M Sell
58,109
-8,315
-13% -$912K 0.12% 172
2013
Q2 		$6.13M Buy
+66,424
New +$6.4M 0.11% 172

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Curian Capital's ALXN Position: Q1 2016 in Review

Curian Capital sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 15,587 shares — an estimated $2.97M sold.

Curian Capital first reported a position in ALXN in Q2 2013 and held it in 11 quarters. The position peaked at $11.7M in Q2 2015. 518 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Curian Capital reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Curian Capital sold 15,587 Alexion Pharmaceuticals shares in Q1 2016, an estimated $2.97M.
  • Curian Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Curian Capital's Alexion Pharmaceuticals position peaked at $11.7M in Q2 2015.
  • 518 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.